Nov 2024
Conyers is acting as Cayman Islands counsel to Edding Group Company Limited (“Edding”) in connection with a merger transaction involving Genor Biopharma Holdings Limited, a Cayman Biotech company listed under the Chapter 18A of the Listing Rules of the Hong Kong Stock Exchange (HKEx: 6998) (“Genor”).
The deal has been announced by Genor and is subject to completion. If completed, the merger would represent, as at the time of writing, the first reverse takeover of a Chapter 18A biotech company and a “back-door listing” for Edding.
Edding is a biopharmaceutical company in the PRC that specialises in anti-infective, cardiovascular and respiratory system-related and other products.
Partner Anna Chong and Associate Michael Yu of Conyers’ Hong Kong office advised on the matter, working alongside Kirkland & Ellis Hong Kong and Haiwen & Partners.